在位于注射器服务项目的可及护理项目中接受治疗的注射吸毒者的丙型肝炎治疗结果
Hepatitis C Treatment Outcomes for People Who Inject Drugs Treated in an Accessible Care Program Located at a Syringe Service Program.
作者信息
Eckhardt Benjamin J, Scherer Matthew, Winkelstein Emily, Marks Kristen, Edlin Brian R
机构信息
Division of Infectious Diseases and Immunology, NYU School of Medicine, New York, New York.
Division of Infectious Diseases, Weill Cornell Medicine, New York, New York.
出版信息
Open Forum Infect Dis. 2018 Mar 6;5(4):ofy048. doi: 10.1093/ofid/ofy048. eCollection 2018 Apr.
Abstract
Hepatitis C virus (HCV) is a significant public health problem that disproportionately afflicts people who inject drugs. We describe outcomes of HCV treatment co-located within a syringe services program (SSP). Fifty-three participants started therapy, and 91% achieved sustained virologic response. SSPs provide an effective venue for HCV treatment.
摘要
丙型肝炎病毒（HCV）是一个严重的公共卫生问题，对注射毒品者的影响尤为严重。我们描述了在注射器服务项目（SSP）中同时开展丙型肝炎病毒治疗的结果。53名参与者开始接受治疗，91%实现了持续病毒学应答。注射器服务项目为丙型肝炎病毒治疗提供了一个有效的场所。
相似文献
1
Hepatitis C Treatment Outcomes for People Who Inject Drugs Treated in an Accessible Care Program Located at a Syringe Service Program.在位于注射器服务项目的可及护理项目中接受治疗的注射吸毒者的丙型肝炎治疗结果
Open Forum Infect Dis. 2018 Mar 6;5(4):ofy048. doi: 10.1093/ofid/ofy048. eCollection 2018 Apr.
2
Accessible Hepatitis C Care for People Who Inject Drugs: A Randomized Clinical Trial.便于注射毒品人群获得丙型肝炎治疗的途径：一项随机临床试验。
JAMA Intern Med. 2022 May 1;182(5):494-502. doi: 10.1001/jamainternmed.2022.0170.
3
Cost of providing co-located hepatitis C treatment at a syringe service program exceeds potential reimbursement: Results from a clinical trial.在注射器服务项目中提供同址丙型肝炎治疗的成本超过了潜在报销额度：一项临床试验的结果。
Drug Alcohol Depend Rep. 2022 Dec;5. doi: 10.1016/j.dadr.2022.100109. Epub 2022 Oct 7.
4
Computerized Tailored Interventions to Enhance Prevention and Screening for Hepatitis C Virus Among People Who Inject Drugs: Protocol for a Randomized Pilot Study.用于加强注射吸毒者丙型肝炎病毒预防和筛查的计算机化定制干预措施：一项随机试点研究的方案
JMIR Res Protoc. 2016 Jan 22;5(1):e15. doi: 10.2196/resprot.4830.
5
Syringe Service Programs for Persons Who Inject Drugs in Urban, Suburban, and Rural Areas - United States, 2013.为城市、城乡和农村地区注射毒品者提供的注射器服务计划-美国，2013 年。
MMWR Morb Mortal Wkly Rep. 2015 Dec 11;64(48):1337-41. doi: 10.15585/mmwr.mm6448a3.
6
Acceptability of Rapid Point-of-Care Hepatitis C Tests Among People Who Inject Drugs and Utilize Syringe-Exchange Programs.在注射毒品者和使用 syringe-exchange 项目的人群中，快速即时检测丙型肝炎的可接受性。
Open Forum Infect Dis. 2016 Apr 6;3(2):ofw075. doi: 10.1093/ofid/ofw075. eCollection 2016 Mar.
7
Effectiveness of pharmacy-based needle/syringe exchange programme for people who inject drugs: a systematic review and meta-analysis.基于药房的针具/注射器交换项目对注射吸毒者的有效性：一项系统评价与荟萃分析。
Addiction. 2017 Feb;112(2):236-247. doi: 10.1111/add.13593. Epub 2016 Oct 19.
8
Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study.在格鲁吉亚，对注射吸毒者进行基于直接作用抗病毒药物的丙型肝炎病毒感染治疗：一项前瞻性队列研究。
Int J Drug Policy. 2018 Dec;62:104-111. doi: 10.1016/j.drugpo.2018.07.016. Epub 2018 Oct 30.
9
Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.印度注射吸毒者中丙型肝炎病毒疾病负担及丙型肝炎病毒服务可及性：一项横断面研究。
Lancet Infect Dis. 2015 Jan;15(1):36-45. doi: 10.1016/S1473-3099(14)71045-X. Epub 2014 Dec 3.
10
Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.从针具和注射器项目进行即时丙肝检测：澳大利亚可行性研究。
Int J Drug Policy. 2019 Oct;72:91-98. doi: 10.1016/j.drugpo.2019.05.012. Epub 2019 May 22.
引用本文的文献
1
Approaches to Offering Hepatitis C Treatment at Syringe Services Programs in the United States: A Scoping Review.美国注射器服务项目中提供丙型肝炎治疗的方法：一项范围综述
Open Forum Infect Dis. 2025 Apr 8;12(4):ofaf211. doi: 10.1093/ofid/ofaf211. eCollection 2025 Apr.
2
Hepatitis C Care in the Greater New Orleans Area: Patient Perspectives on the Barriers and Facilitators to Care.大新奥尔良地区的丙型肝炎护理：患者对护理障碍和促进因素的看法。
J Health Care Poor Underserved. 2025;36(1):257-283. doi: 10.1353/hpu.2025.a951596.
3
Hepatitis C Treatment in Kentucky Medicaid Recipients with Concurrent Opioid Use Disorder: A Cross-Sectional Study.肯塔基州医疗补助计划中同时患有阿片类物质使用障碍的丙型肝炎患者的治疗：一项横断面研究。
J Gen Intern Med. 2025 Jan 21. doi: 10.1007/s11606-025-09356-2.
4
Elimination of HCV Infection: Recent Epidemiological Findings, Barriers, and Strategies for the Coming Years.消除 HCV 感染：近年流行病学发现、障碍及未来策略。
Viruses. 2024 Nov 19;16(11):1792. doi: 10.3390/v16111792.
5
Reduced injection risk behavior with co-located hepatitis C treatment at a syringe service program: The accessible care model.在美沙酮维持治疗点实施共置性丙型肝炎治疗可降低注射风险行为：可及性护理模式。
PLoS One. 2024 Aug 29;19(8):e0308102. doi: 10.1371/journal.pone.0308102. eCollection 2024.
6
Distrust in the Health Care System and Adherence to Direct-Acting Antiviral Therapy among People with Hepatitis Who Inject Drugs.对医疗保健系统的不信任与接受直接抗病毒治疗的坚持：注射毒品的肝炎患者。
Viruses. 2024 Aug 16;16(8):1304. doi: 10.3390/v16081304.
7
Polysubstance Use and Related Risk Behaviors among People Who Inject Drugs in Kenya Preparing for Hepatitis C Virus Treatment.肯尼亚准备接受丙型肝炎病毒治疗的注射吸毒者的多药物使用和相关风险行为。
Viruses. 2024 Aug 10;16(8):1277. doi: 10.3390/v16081277.
8
Barriers to Hepatitis C Treatment and Interest in Telemedicine-Based Care Among Clients of a Syringe Access Program.丙肝治疗的障碍以及注射器交换项目服务对象对远程医疗护理的兴趣
Open Forum Infect Dis. 2024 Feb 13;11(3):ofae088. doi: 10.1093/ofid/ofae088. eCollection 2024 Mar.
9
"Treated like a Human Being": perspectives of people who inject drugs attending low-threshold HCV treatment at a syringe service program in New York City.“被当作人对待”：在纽约市的一个注射器服务项目中接受低门槛 HCV 治疗的注射吸毒者的观点。
Harm Reduct J. 2023 Jul 27;20(1):95. doi: 10.1186/s12954-023-00831-9.
10
Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study.在丙型肝炎病毒感染者中使用直接作用抗病毒药物：一项定性研究。
Int J Equity Health. 2023 Jun 6;22(1):112. doi: 10.1186/s12939-023-01924-4.
本文引用的文献
1
High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic.在城市基层医疗诊所，采用直接作用抗病毒药物治疗的吸毒者，其 HCV 治愈率较高。
Int J Drug Policy. 2017 Sep;47:196-201. doi: 10.1016/j.drugpo.2017.07.021. Epub 2017 Aug 12.
2
Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.在目标性基层医疗保健环境中为高度边缘化且当前有药物注射史的丙型肝炎人群提供直接作用抗病毒治疗。
Int J Drug Policy. 2017 Sep;47:209-215. doi: 10.1016/j.drugpo.2017.05.032. Epub 2017 Jun 4.
3
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.依巴司韦/格拉瑞韦治疗接受阿片类激动剂治疗的丙型肝炎病毒感染者：一项随机试验。
Ann Intern Med. 2016 Nov 1;165(9):625-634. doi: 10.7326/M16-0816. Epub 2016 Aug 9.
4
Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013.2003 - 2013年美国丙型肝炎病毒相关死亡率上升
Clin Infect Dis. 2016 May 15;62(10):1287-1288. doi: 10.1093/cid/ciw111. Epub 2016 Mar 1.
5
Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program.在阿片类激动剂治疗项目中采用三联疗法成功治疗慢性丙型肝炎。
Int J Drug Policy. 2015 Oct;26(10):1014-9. doi: 10.1016/j.drugpo.2015.08.008. Epub 2015 Aug 20.
6
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States.美国医疗补助计划对索磷布韦治疗丙型肝炎病毒感染的报销限制。
Ann Intern Med. 2015 Aug 4;163(3):215-23. doi: 10.7326/M15-0406.
7
Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.1999年至2011年期间，澳大利亚参与针头和注射器项目的注射吸毒者中丙型肝炎治疗的接受情况。
J Viral Hepat. 2014 Mar;21(3):198-207. doi: 10.1111/jvh.12129. Epub 2013 Jul 1.
8
Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.联合干预措施预防注射吸毒人群中 HCV 传播：抗病毒治疗、针具和注射器方案以及阿片类物质替代疗法的影响建模。
Clin Infect Dis. 2013 Aug;57 Suppl 2(Suppl 2):S39-45. doi: 10.1093/cid/cit296.
9
Epidemiology and natural history of HCV infection.丙型肝炎病毒感染的流行病学和自然史。
Nat Rev Gastroenterol Hepatol. 2013 Sep;10(9):553-62. doi: 10.1038/nrgastro.2013.107. Epub 2013 Jul 2.
10
Mixed genotype hepatitis C infections and implications for treatment.混合基因型丙型肝炎感染及其治疗意义。
Hepatology. 2014 Mar;59(3):1209. doi: 10.1002/hep.26544. Epub 2014 Jan 13.
Zotero 插件